Distal Renal Tubular Acidosis (dRTA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Distal Renal Tubular Acidosis (dRTA) Market Outlook
Thelansis’s “Distal Renal Tubular
Acidosis (dRTA) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Distal Renal Tubular Acidosis
(dRTA) treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
Distal
Renal Tubular Acidosis (dRTA) Overview
Distal
renal tubular acidosis (dRTA) or RTA type-I comprises a group of disorders in
which the excretion of hydrogen ions or reabsorption of filtered HCO3 is
impaired, resulting in chronic metabolic acidosis with a standard anion gap. In
children affected by dRTA, there is stunted growth, loss of appetite,
constipation, vomiting, nephrocalcinosis, polydipsia and polyuria, weakness and
muscle paralysis due to hypokalemia. DRTA can be autosomal dominant or
autosomal recessive. Autosomal recessive dRTA manifests itself in the first
months of life and progresses with nephrocalcinosis and early or late hearing
loss. Autosomal dominant dRTA is less severe, occurs during adolescence or
adulthood, and may or may not develop nephrocalcinosis. In alpha-intercalated cells
of the collecting duct, the acid load is deposited into the urine as titratable
acids (phosphates) and ammonium. Mutations in the genes ATP6V1B1, ATP6V0A4, and
SLC4A1 cause autosomal recessive dRTA, which encode subunits a4 and B1 of
V-ATPase and the AE1 bicarbonate/chloride exchanger, respectively. Autosomal
dominant dRTA, on the other hand, is only related to AE1 mutations.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment